Completed NA INTERVENTIONAL 2-arm NCT01882920

Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)

Cytoreductive Surgery With Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) - Goal Directed Therapy vs. Standard Fluid Therapy. Prospective Randomized Study

Sponsor: Regina Elena Cancer Institute

Conditions Primary Peritoneal Neoplasm Secondary Peritoneal Neoplasm

Interventions Conventional Intravenous Fluid therapy Goal Directed Intravenous Restrictive Fluid Therapy

Updated 6 times since 2017 Last updated: Apr 25, 2017 Started: Jun 30, 2010 Primary completion: Jun 30, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Primary Peritoneal Neoplasm and Secondary Peritoneal Neoplasm and is currently completed. Regina Elena Cancer Institute leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
May 2017 — Jun 2018 [monthly]

Completed NA

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Recruiting NA

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regina Elena Cancer Institute

Data source: Regina Elena Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy